Baichuan Xu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Baichuan Xu has a total of 39 co-authors. Here are the top co-authors by number of shared publications:
- Jinghong Zhao
Department of Nephrology, Chongqing Key Laboratory of Prevention and Treatment of Kidney Disease, Chongqing Clinical Research Center of Kidney and Urology Diseases, Xinqiao Hospital, Army Medical University (Third Military Medical University), Chongqing, China
2 shared publications Jun Chen
Army Medical University (Third Military Medical University), Chongqing, China
2 shared publications- Junping Wang
State Key Laboratory of Trauma and Chemical Poisoning, Institute of Combined Injury, Chongqing Engineering Research Center for Nanomedicine, College of Preventive Medicine, Army Medical University (Third Military Medical University), Chongqing, China
2 shared publications Qigang Lan
Xinqiao Hospital, Army Medical University, Chongqing, China
2 shared publications- Yang Xu
Army Medical University (Third Military Medical University), Chongqing, China
2 shared publications - Fang Chen
Third Military Medical University, Chongqing, China
1 shared publication
Latest Publications
- 25 September 2026
- Published by American Society of Hematology in Blood
HIF-1α/ADPGK-driven glycolytic reprogramming provokes platelet hyperactivation by fueling RHOA lactylation
Platelet hyperactivation is the primary driver of thrombosis, which frequently occurs under physiological and pathological hypoxic conditions. Platelet activation is energy-intensive, while it is puzzling to explain hypoxia-associated platelet hyperactivation with energy metabolism. Here, we demonstrate that HIF-1α-driven glycolytic reprogramming induces platelet hyperactivation by fueling RHOA activation in chronic kidney disease (CKD) and high-altitude cohorts. We show that CKD-associated or hypoxia-induced upregulation of HIF-1α stabilizes ADP-dependent glucokinase (ADPGK) by shielding its lysine 125 from ubiquitin-mediated degradation, and ADPGK then utilizes ADP to drive glycolysis, resulting in lactate accumulation in platelets. Subsequently, accumulated lactate induces RHOA lactylation at lysine 7 to enhance its activation, thereby promoting cytoskeletal remodeling and platelet hyperactivation. Pharmacological inhibition of ADPGK with a screened compound Z809269780 effectively alleviates hypoxia-associated platelet hyperactivation and thrombosis. Our findings uncover an unrecognized non-histone lactylation mechanism of platelet hyperactivation and identify a potential therapeutic avenue for hypoxia-induced thrombotic complications.
- 25 September 2026
- Published by American Society of Hematology in Blood
HIF-1α/ADPGK-driven glycolytic reprogramming provokes platelet hyperactivation by fueling RHOA lactylation
Platelet hyperactivation is the primary driver of thrombosis, which frequently occurs under physiological and pathological hypoxic conditions. Platelet activation is energy-intensive, while it is puzzling to explain hypoxia-associated platelet hyperactivation with energy metabolism. Here, we demonstrate that HIF-1α-driven glycolytic reprogramming induces platelet hyperactivation by fueling RHOA activation in chronic kidney disease (CKD) and high-altitude cohorts. We show that CKD-associated or hypoxia-induced upregulation of HIF-1α stabilizes ADP-dependent glucokinase (ADPGK) by shielding its lysine 125 from ubiquitin-mediated degradation, and ADPGK then utilizes ADP to drive glycolysis, resulting in lactate accumulation in platelets. Subsequently, accumulated lactate induces RHOA lactylation at lysine 7 to enhance its activation, thereby promoting cytoskeletal remodeling and platelet hyperactivation. Pharmacological inhibition of ADPGK with a screened compound Z809269780 effectively alleviates hypoxia-associated platelet hyperactivation and thrombosis. Our findings uncover an unrecognized non-histone lactylation mechanism of platelet hyperactivation and identify a potential therapeutic avenue for hypoxia-induced thrombotic complications.
- Open Access
- 3 June 2026
- Published by American Society of Hematology in Blood
- Vol. 148 (10) , 1344-1358
GLUL pitches in thrombocytopoiesis by restricting ammonia accumulation during megakaryocyte maturation
Polyploidization resulted from massive DNA synthesis is crucial for megakaryocyte maturation, while the regulatory mechanisms of cell fitness upon this special cellular process remain poorly understood. Here, we reveal that glutamine synthetase (GLUL) facilitates thrombocytopoiesis by restricting ammonia accumulation during polyploidization. GLUL is found to be distinctly expressed in platelet-producing megakaryocytes and increasingly elevated with the progression of polyploidization, and GLUL deficiency impairs megakaryocyte maturation and platelet production. Mechanistically, GLUL detoxifies ammonia derived from adenosine deaminase acting on RNA 1 (ADAR1)-mediated double-stranded RNA (dsRNA) editing in megakaryocytes undergoing polyploidization. Ammonia accumulation is observed in megakaryocytes defective in GLUL, leading to lysosomal and mitochondrial damage and even cell death. Fulvotomentoside A (FtA) is identified as a potential GLUL agonist with the capacity to promote thrombocytopoiesis in mice after radiation and chemotherapy injury. Our findings uncover the biological significance of GLUL in megakaryocyte maturation and provide a new avenue for regulating thrombocytopoiesis.
- 3 June 2026
- Published by American Society of Hematology in Blood
- Vol. 148 (10) , 1344-1358
Open AccessGLUL pitches in thrombocytopoiesis by restricting ammonia accumulation during megakaryocyte maturation
Polyploidization resulted from massive DNA synthesis is crucial for megakaryocyte maturation, while the regulatory mechanisms of cell fitness upon this special cellular process remain poorly understood. Here, we reveal that glutamine synthetase (GLUL) facilitates thrombocytopoiesis by restricting ammonia accumulation during polyploidization. GLUL is found to be distinctly expressed in platelet-producing megakaryocytes and increasingly elevated with the progression of polyploidization, and GLUL deficiency impairs megakaryocyte maturation and platelet production. Mechanistically, GLUL detoxifies ammonia derived from adenosine deaminase acting on RNA 1 (ADAR1)-mediated double-stranded RNA (dsRNA) editing in megakaryocytes undergoing polyploidization. Ammonia accumulation is observed in megakaryocytes defective in GLUL, leading to lysosomal and mitochondrial damage and even cell death. Fulvotomentoside A (FtA) is identified as a potential GLUL agonist with the capacity to promote thrombocytopoiesis in mice after radiation and chemotherapy injury. Our findings uncover the biological significance of GLUL in megakaryocyte maturation and provide a new avenue for regulating thrombocytopoiesis.
- Open Access
- 24 January 2025
- Published by Wiley in Advanced Science
- Vol. 12 (13) , e2411914
IRAP Drives Ribosomal Degradation to Refuel Energy for Platelet Activation during Septic Thrombosis
Platelets play crucial roles in multiple pathophysiological processes after energy‐dependent activation. It is puzzling how such a small cellular debris has abundant energy supply. In this study, it is shown that insulin‐regulated aminopeptidase (IRAP), a type II transmembrane protein, is a key regulator for platelet activation by promoting energy regeneration during septic thrombosis. Through interaction with certain endosome membrane proteins, IRAP can not only promote granule release, but also facilitate lysosomal degradation of theoretically discarded ribosomes in an mTORC1‐ and S‐acylation‐dependent manner in activated platelets. Plentiful amino acids obtained from IRAP‐mediated ribophagy are recruited to aerobic glycolysis and then promote energy metabolism reprogramming, thereby producing abundant energy for platelet life extension and prolonged activation. Consequently, targeted blocking IRAP can dramatically alleviate platelet hyperactivation and septic thrombosis.
- 24 January 2025
- Published by Wiley in Advanced Science
- Vol. 12 (13) , e2411914
Open AccessIRAP Drives Ribosomal Degradation to Refuel Energy for Platelet Activation during Septic Thrombosis
Platelets play crucial roles in multiple pathophysiological processes after energy‐dependent activation. It is puzzling how such a small cellular debris has abundant energy supply. In this study, it is shown that insulin‐regulated aminopeptidase (IRAP), a type II transmembrane protein, is a key regulator for platelet activation by promoting energy regeneration during septic thrombosis. Through interaction with certain endosome membrane proteins, IRAP can not only promote granule release, but also facilitate lysosomal degradation of theoretically discarded ribosomes in an mTORC1‐ and S‐acylation‐dependent manner in activated platelets. Plentiful amino acids obtained from IRAP‐mediated ribophagy are recruited to aerobic glycolysis and then promote energy metabolism reprogramming, thereby producing abundant energy for platelet life extension and prolonged activation. Consequently, targeted blocking IRAP can dramatically alleviate platelet hyperactivation and septic thrombosis.